Natural History of Paclitaxel-associated Acute Pain Syndrome: A Case Report of Rare Side Effect of Paclitaxel

Siti Salima; Ali Budi Harsono; Aisyah Aisyah; Kemala Mantilidewi

doi:10.3889/oamjms.2021.7031

Authors

Siti Salima Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Padjadjaran, Dr. Hasan Sadikin Hospital, Bandung, West Java, Indonesia https://orcid.org/0000-0001-6342-321X
Ali Budi Harsono Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Padjadjaran, Dr. Hasan Sadikin Hospital, Bandung, West Java, Indonesia
Aisyah Aisyah Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Padjadjaran, Dr. Hasan Sadikin Hospital, Bandung, West Java, Indonesia
Kemala Mantilidewi Department of Obstetrics and Gynecology, Faculty of Medicine, Universitas Padjadjaran, Dr. Hasan Sadikin Hospital, Bandung, West Java, Indonesia https://orcid.org/0000-0003-4588-8018

DOI:

https://doi.org/10.3889/oamjms.2021.7031

Keywords:

Chemotherapy-induced neuropathic pain, Acute pain syndrome, Paclitaxel, Carboplatin, Ovarian cancer

Abstract

BACKGROUND: One of the harshest side effects following anticancer agent treatments is chemotherapy-induced neuropathic pain. After surgical staging, chemotherapy combination of paclitaxel carboplatin could be a choice of therapy for Stage II or more advanced stage of ovarian cancer. Different side effects may appear after the application of paclitaxel.

CASE REPORT: Here, we show an uncommon case of paclitaxel-acute pain syndrome (P-APS), and how we deal with such cases according to our experiences. One uncommon side effect is P-APS, which can be treated effectively with the administration of non-steroidal anti-inflammatory drugs, corticosteroid, and supportive therapy.

CONCLUSION: One uncommon side effect of Paclitaxel induced neuropathic can be treated effectively with the administration of non-steroidal anti inflammatory drugs, corticosteroid, and supportive therapy.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Plum Analytics Artifact Widget Block

References

Society AC. Key Statistics for Ovarian Cancer Atlanta: Leo and Gloria Rosen Family; 2021. Available from: https://www.cancer.org/cancer/ovarian-cancer/about/key-statistics.html [Last accessed on 2021 Feb 25].

Institute NC. Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Ovarian Cancer; 2021. Available from: https://seer.cancer.gov/statfacts/html/ovary.html [Last accessed on 2021Feb 25].

Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014;384(9951):1376-88. https://doi.org/10.1016/s0140-6736(13)62146-7 PMıd:24767708 DOI: https://doi.org/10.1016/S0140-6736(13)62146-7

Slatnik CL, Duff E. Ovarian cancer: Ensuring early diagnosis. Nurse Pract. 2015;40(9):47-54. https://doi.org/10.1097/01.npr.0000450742.00077.a2 PMıd:26274886 DOI: https://doi.org/10.1097/01.NPR.0000450742.00077.a2

Querleu D, Planchamp F, Chiva L, Fotopoulou C, Barton D, Cibula D, et al. European society of gynaecological oncology (ESGO) guidelines for ovarian cancer surgery. Int J Gynecol Cancer. 2017;27(7):1534-42. https://doi.org/10.1097/igc.0000000000001041 PMıd:30814245 DOI: https://doi.org/10.1097/IGC.0000000000001041

Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, et al. NCCN guidelines ınsights: Ovarian cancer, version 1.2019: Featured updates to the NCCN guidelines. J Natl Comp Cancer Network. 2019;17(8):896-909. https://doi.org/10.6004/jnccn.2019.0039 PMıd:31390583 DOI: https://doi.org/10.6004/jnccn.2019.0039

Gornstein EL, Schwarz TL. Neurotoxic mechanisms of paclitaxel are local to the distal axon and independent of transport defects. Exp Neurol. 2017;288:153-66. https://doi.org/10.1016/j.expneurol.2016.11.015 PMıd:27894788 DOI: https://doi.org/10.1016/j.expneurol.2016.11.015

Da Costa R, Passos GF, Quintão NL, Fernandes ES, Maia JR, Campos MM, et al. Taxane‐induced neurotoxicity: Pathophysiology and therapeutic perspectives. Br J Pharmacol. 2020;177(14):3127-46. https://doi.org/10.1111/bph.15086 PMıd:32352155 DOI: https://doi.org/10.1111/bph.15086

Rowinsky E, Eisenhauer E, Chaudhry V, Arbuck S, Donehower RC, editors. Clinical Toxicities Encountered with Paclitaxel (Taxol). Seminars in Oncology; 1993.

Garrison JA, McCune JS, Livingston RB, Linden HM, Gralow JR, Ellis GK, et al. Myalgias and arthralgias associated with paclitaxel. Oncology (Williston Park, NY). 2003;17(2):271-7; discussion 81. PMıd:12632867

Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, Kamal A, et al. Further data supporting that paclitaxel‐associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1. Cancer. 2012;118(20):5171-8. https://doi.org/10.1002/cncr.27489 PMıd:22415454 DOI: https://doi.org/10.1002/cncr.27489

Loprinzi CL, Reeves BN, Dakhil SR, Sloan JA, Wolf SL, Burger KN, et al. Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol. 2011;29(11):1472-8. https://doi.org/10.1200/jco.2010.33.0308 PMıd:21383290 DOI: https://doi.org/10.1200/JCO.2010.33.0308

Quintão NL, Santin JR, Stoeberl LC, Corrêa TP, Melato J, Costa R. Pharmacological treatment of chemotherapyınduced neuropathic pain: PPARγ agonists as a promising tool. Front Neurosci. 2019;13:907. https://doi.org/10.3389/fnins.2019.00907 PMıd:31555078 DOI: https://doi.org/10.3389/fnins.2019.00907

Zajączkowska R, Kocot-Kępska M, Leppert W, Wrzosek A, Mika J, Wordliczek J. Mechanisms of chemotherapy-ınduced peripheral neuropathy. Int J Mol Sci. 2019;20(6):1451. https://doi.org/10.3390/ijms20061451 PMıd:30909387 DOI: https://doi.org/10.3390/ijms20061451

Fallon MT. Neuropathic pain in cancer. Br J Anaesth. 2013;111(1):105-11. PMıd:23794652 DOI: https://doi.org/10.1093/bja/aet208

Miltenburg N, Boogerd W. Chemotherapy-induced neuropathy: A comprehensive survey. Cancer Treatment Rev. 2014;40(7):872-82. https://doi.org/10.1016/j.ctrv.2014.04.004 PMıd:24830939 DOI: https://doi.org/10.1016/j.ctrv.2014.04.004

Licht T, Keilani M, Crevenna R. Chemotherapy-induced peripheral neuropathy (CIPN). Memo 2021;14:1-5. https://doi.org/10.1007/s12254-021-00688-3 DOI: https://doi.org/10.1007/s12254-021-00688-3

Colvin LA. Chemotherapy-induced peripheral neuropathy (CIPN): Where are we now? Pain 2019;160(Suppl 1):S1-10. https://doi.org/10.1097/j.pain.0000000000001540 PMıd:31008843 DOI: https://doi.org/10.1097/j.pain.0000000000001540

Xu J, Zhang L, Xie M, Li Y, Huang P, Saunders TL, et al. Role of complement in a rat model of paclitaxel-induced peripheral neuropathy. J Immunol. 2018;200(12):4094-101. https://doi.org/10.4049/jimmunol.1701716 PMıd:29695418 DOI: https://doi.org/10.4049/jimmunol.1701716

Jimenez-Andrade JM, Peters CM, Mejia NA, Ghilardi JR, Kuskowski MA, Mantyh PW. Sensory neurons and their supporting cells located in the trigeminal, thoracic and lumbar ganglia differentially express markers of injury following intravenous administration of paclitaxel in the rat. Neurosci Lett. 2006;405(1-2):62-7. https://doi.org/10.1016/j.neulet.2006.06.043 PMıd:16854522 DOI: https://doi.org/10.1016/j.neulet.2006.06.043

Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4(4):253-65. PMıd:15057285 DOI: https://doi.org/10.1038/nrc1317

Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: Diagnosis, treatment, and prevention. Neurooncology. 2012;14(Suppl 4):iv45-54. https://doi.org/10.1093/neuonc/nos203 PMıd:23095830 DOI: https://doi.org/10.1093/neuonc/nos203

Han Y, Smith MT. Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN). Frontiers in pharmacology. 2013;4:156. https://doi.org/10.3389/fphar.2013.00156 PMıd:24385965 DOI: https://doi.org/10.3389/fphar.2013.00156

Salvemini D, Little JW, Doyle T, Neumann WL. Roles of reactive oxygen and nitrogen species in pain. Free Radical Biology and Medicine. 2011;51(5):951-66. https://doi.org/10.1016/j.freeradbiomed.2011.01.026 PMıd:21277369 DOI: https://doi.org/10.1016/j.freeradbiomed.2011.01.026

Moran MM, Xu H, Clapham DE. TRP ion channels in the nervous system. Curr Opin Neurobiol. 2004;14(3):362-9. https://doi.org/10.1016/j.conb.2004.05.003 PMıd:15194117 DOI: https://doi.org/10.1016/j.conb.2004.05.003

Wang T, Qin L, Liu B, Liu Y, Wilson B, Eling TE, et al. Role of reactive oxygen species in LPS‐induced production of prostaglandin E2 in microglia. J Neurochem. 2004;88(4):939-47. https://doi.org/10.1046/j.1471-4159.2003.02242.x PMıd:14756815 DOI: https://doi.org/10.1046/j.1471-4159.2003.02242.x

Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J. Use of low-dose oral prednisone to prevent paclitaxel-induced arthralgias and myalgias. Gynecol Oncol. 1999;72(1):100-1. https://doi.org/10.1006/gyno.1998.5226 PMıd:9889038 DOI: https://doi.org/10.1006/gyno.1998.5226

Liu CC, Lu N, Cui Y, Yang T, Zhao ZQ, Xin WJ, et al. Prevention of paclitaxel-induced allodynia by minocycline: Effect on loss of peripheral nerve fibers and infiltration of macrophages in rats. Mol Pain. 2010;6:76. https://doi.org/10.1186/1744-8069-6-76 PMıd:21050491 DOI: https://doi.org/10.1186/1744-8069-6-76

Saito Y, Kobayashi M, Yamada T, Sakakibara-Konishi J, Shinagawa N, Kinoshita I, et al. Efficacy of additional dexamethasone administration for the attenuation of paclitaxel-associated acute pain syndrome. Support Care Cancer. 2020;28(1):221-7. https://doi.org/10.1007/s00520-019-04808-y PMıd:31016422 DOI: https://doi.org/10.1007/s00520-019-04808-y